Yabao Pharmaceutical (600351.SH) announced semi-annual results, with net profit of 178 million yuan to mother, an increase of 1.83% over the previous year

According to Zhitong Finance App News, Yabao Pharmaceutical (600351.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1,145 billion yuan, an increase of 0.49%; net profit attributable to shareholders of listed companies was 178 million yuan, up 1.83% year on year; after deducting non-net profit of 179 million yuan, up 12.28% year on year; basic earnings per share were 0.2566 yuan. The company plans to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders.

During the reporting period, the company achieved operating revenue of 1,145 billion yuan, up 0.49% year on year. Among them: pharmaceutical production revenue increased 4.26% year on year, mainly due to increased revenue from major products such as mecobalamin tablets and moxapride citrate tablets; pharmaceutical wholesale revenue fell 19.11% year on year, mainly due to a decrease in pharmaceutical wholesale revenue.